Bruce Albala

1.4k total citations
21 papers, 432 citations indexed

About

Bruce Albala is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Bruce Albala has authored 21 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 7 papers in Pharmacology and 7 papers in Physiology. Recurrent topics in Bruce Albala's work include Dementia and Cognitive Impairment Research (9 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Alzheimer's disease research and treatments (6 papers). Bruce Albala is often cited by papers focused on Dementia and Cognitive Impairment Research (9 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Alzheimer's disease research and treatments (6 papers). Bruce Albala collaborates with scholars based in United States, United Kingdom and Japan. Bruce Albala's co-authors include Karen Ritchie, Craig Ritchie, Christopher Randolph, John Harrison, Jeffrey Kaye, Michael T. Ropacki, Joel H. Kramer, June Kaplow, Jessica A. Ash and Marion Mortamais and has published in prestigious journals such as Stroke, Scientific Reports and Journal of Alzheimer s Disease.

In The Last Decade

Bruce Albala

20 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce Albala United States 9 205 189 95 84 82 21 432
Hyun Jeong Han South Korea 16 211 1.0× 243 1.3× 119 1.3× 37 0.4× 59 0.7× 51 595
Kasia Lobello United States 8 112 0.5× 116 0.6× 146 1.5× 39 0.5× 47 0.6× 10 434
Miia Kivipelto Sweden 11 177 0.9× 163 0.9× 22 0.2× 14 0.2× 31 0.4× 37 440
Gustavo Jimenez‐Maggiora United States 13 143 0.7× 202 1.1× 19 0.2× 13 0.2× 36 0.4× 23 391
Ping Chiao United States 8 266 1.3× 242 1.3× 46 0.5× 31 0.4× 84 1.0× 19 436
Lance Macaulay Australia 8 170 0.8× 150 0.8× 44 0.5× 27 0.3× 46 0.6× 24 480
Li‐Kai Huang Taiwan 9 160 0.8× 72 0.4× 56 0.6× 23 0.3× 34 0.4× 22 416
Nada Abdalla United States 5 171 0.8× 224 1.2× 44 0.5× 23 0.3× 37 0.5× 7 446
Tarja Järvenpää Finland 8 96 0.5× 140 0.7× 86 0.9× 24 0.3× 58 0.7× 11 341
Mohan Giri China 12 214 1.0× 75 0.4× 51 0.5× 22 0.3× 18 0.2× 42 637

Countries citing papers authored by Bruce Albala

Since Specialization
Citations

This map shows the geographic impact of Bruce Albala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Albala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Albala more than expected).

Fields of papers citing papers by Bruce Albala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Albala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Albala. The network helps show where Bruce Albala may publish in the future.

Co-authorship network of co-authors of Bruce Albala

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Albala. A scholar is included among the top collaborators of Bruce Albala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Albala. Bruce Albala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Skirrow, Caroline, et al.. (2024). Storyteller in ADNI4: Application of an early Alzheimer's disease screening tool using brief, remote, and speech‐based testing. Alzheimer s & Dementia. 20(10). 7248–7262. 3 indexed citations
2.
Albala, Bruce, Susan De Santi, Gregory Klein, et al.. (2023). The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB). Alzheimer s & Dementia. 20(1). 695–708. 4 indexed citations
3.
Miller, Melanie J., Rachel L. Nosheny, Bruce Albala, et al.. (2023). ADNI4’s novel remote screening approach ‐ weighing priorities in participant selection. Alzheimer s & Dementia. 19(S18).
4.
Doherty, T., Michelle Gee, Paul Maruff, et al.. (2022). Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease. Alzheimer Disease & Associated Disorders. 36(3). 185–191. 2 indexed citations
5.
Edgar, Chris J., Eric Siemers, Paul Maruff, et al.. (2021). Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer s Disease. 83(2). 915–925. 12 indexed citations
6.
Bruckner, Tim A., Daniel M. Parker, Scott M. Bartell, et al.. (2021). Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. Scientific Reports. 11(1). 3081–3081. 30 indexed citations
7.
8.
Roberts, Claire, Michio Kanekiyo, June Kaplow, & Bruce Albala. (2019). P1‐041: APOE4 STATUS AND AMYLOID BURDEN DIFFERENCES ACROSS REGIONS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM. Alzheimer s & Dementia. 15(7S_Part_4). 1 indexed citations
9.
10.
Yasuda, Sanae, Satoshi Itō, Robert Lai, et al.. (2018). P1‐040: ELENBECESTAT, A NOVEL BACE INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS AND TOLERABILITY IN JAPANESE SUBJECTS WITH MULTIPLE DOSINGS. Alzheimer s & Dementia. 14(7S_Part_5). 2 indexed citations
11.
Maruff, Paul, et al.. (2017). [O2–16–02]: ACCEPTABILITY, USABILITY, VALIDITY AND SENSITIVITY OF COGNITION ASSESSED IN UNSUPERVISED SETTINGS. Alzheimer s & Dementia. 13(7S_Part_12). 3 indexed citations
12.
Moriyama, Tomoyuki, et al.. (2017). [P3–037]: PRECLINICAL STUDIES WITH ELENBECESTAT, A NOVEL BACE1 INHIBITOR, SHOW NO EVIDENCE OF HYPOPIGMENTATION. Alzheimer s & Dementia. 13(7S_Part_19). 5 indexed citations
13.
Albala, Bruce, Robert Lai, Jagadeesh Aluri, et al.. (2017). [P2–003]: ELENBECESTAT PHARMACOKINETIC DRUG‐DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS. Alzheimer s & Dementia. 13(7S_Part_12). 2 indexed citations
14.
Mortamais, Marion, Jessica A. Ash, John Harrison, et al.. (2016). Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimer s & Dementia. 13(4). 468–492. 145 indexed citations
15.
Ritchie, Karen, Michael T. Ropacki, Bruce Albala, et al.. (2016). Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. Alzheimer s & Dementia. 13(2). 186–195. 69 indexed citations
16.
Matijevic, Mark, Hideki Watanabe, Yoshiaki Sato, et al.. (2015). P4‐163: A single dose of the beta‐secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys. Alzheimer s & Dementia. 11(7S_Part_18). 7 indexed citations
17.
Bernier, François P., Yoshiaki Sato, Mark Matijevic, et al.. (2013). P4–411: Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimer s & Dementia. 9(4S_Part_22). 17 indexed citations
18.
Albala, Bruce, June Kaplow, Robert Lai, et al.. (2012). S4‐04‐01: CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609. Alzheimer s & Dementia. 8(4S_Part_20). 12 indexed citations
19.
Lai, Robert, Bruce Albala, June Kaplow, et al.. (2012). O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing. Alzheimer s & Dementia. 8(4S_Part_3). 46 indexed citations
20.
Zhang, Rui Lan, Chunling Zhang, Li Zhang, et al.. (2008). Synergistic Effect of an Endothelin Type A Receptor Antagonist, S-0139, With rtPA on the Neuroprotection After Embolic Stroke. Stroke. 39(10). 2830–2836. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyun Jeong Han Breakdown of academic impact, for papers by Kasia Lobello Breakdown of academic impact, for papers by Miia Kivipelto Breakdown of academic impact, for papers by Gustavo Jimenez‐Maggiora Breakdown of academic impact, for papers by Ping Chiao Breakdown of academic impact, for papers by Lance Macaulay Breakdown of academic impact, for papers by Li‐Kai Huang Breakdown of academic impact, for papers by Nada Abdalla Breakdown of academic impact, for papers by Tarja Järvenpää Breakdown of academic impact, for papers by Mohan Giri
Rankless by CCL
2026